HCM
ACAD icon

Highbridge Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Highbridge Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,068
Closed -$243K – 1195
2017
Q1 		$243K Buy
+7,068
New +$249K ﹤0.01% 1249
2016
Q2 		– Sell
-31,648
Closed -$885K – 1342
2016
Q1 		$885K Buy
+31,648
New +$690K 0.01% 772

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Highbridge Capital Management's ACAD Position: Q2 2017 in Review

Highbridge Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2017, closing a stake of 7,068 shares — an estimated $243K sold.

Highbridge Capital Management first reported a position in ACAD in Q1 2016 and held it in 2 quarters. The position peaked at $885K in Q1 2016. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Highbridge Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 7,068 Acadia Pharmaceuticals shares in Q2 2017, an estimated $243K.
  • Highbridge Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Highbridge Capital Management's Acadia Pharmaceuticals position peaked at $885K in Q1 2016.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.